Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL456821 | 1.00 | ALDH1A1 (0.62) | ALDH1A1LMNATHRBNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL1116447 | 0.98 | ALDH1A1 (0.61) | ALDH1A1LMNATHRBNPC1RAB9A | |
| SCHEMBL8764646 | 0.79 | CYP2D6 (0.51) | ALDH1A1LMNATHRBNPC1RAB9A | |
| SCHEMBL28275043 | 0.77 | ALDH1A1 (1.00) | ALDH1A1LMNATHRBNPC1RAB9A | |
| SCHEMBL28275041 | 0.77 | ALDH1A1 (1.00) | ALDH1A1LMNATHRBNPC1RAB9A | |
| SCHEMBL7442470 | 0.77 | ALDH1A1 (0.61) | ALDH1A1LMNATHRBNPC1RAB9A | |
| SCHEMBL10823736 | 0.76 | NPC1 (0.54) | ALDH1A1LMNATHRBNPC1RAB9A | |
| SCHEMBL4996449 | 0.76 | ALDH1A1 (0.57) | ALDH1A1LMNATHRBNPC1RAB9A | |
| SCHEMBL18223966 | 0.75 | ALDH1A1 (0.56) | ALDH1A1LMNATHRB | |
| SCHEMBL13652067 | 0.75 | SMN1; SMN2 (0.64) | ALDH1A1LMNANPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250242053-A1 | RECOMBINANT THERAPEUTIC FMR1 CONSTRUCTS AND METHODS OF TREATING FRAGILE X SYNDROME AND RELATED DISORDERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2025-07-31 | — | — | US | disclosed |
| EP-4584289-A2 | THERAPEUTIC MOLECULES | UEA Enterprises Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| US-20250136651-A1 | RECOMBINANT OPTIMIZED MECP2 CASSETTES AND METHODS FOR TREATING RETT SYNDROME AND RELATED DISORDERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2025-05-01 | — | — | US | disclosed |
| EP-4514980-A1 | RECOMBINANT THERAPEUTIC FMR1 CONSTRUCTS AND METHODS OF TREATING FRAGILE X SYNDROME AND RELATED DISORDERS | The University Court Of The University of Edinburgh (GB) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023114816-A9 | RECOMBINANT OPTIMIZED GALC CONSTRUCTS AND METHODS FOR TREATING GALC-ASSOCIATED DISORDERS | NEUROGENE INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| CN-119301258-A | Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders | 爱丁堡大学董事会 | 2025-01-10 | — | — | CN | disclosed |
| EP-4473121-A1 | RECOMBINANT OPTIMIZED MECP2 CASSETTES AND METHODS FOR TREATING RETT SYNDROME AND RELATED DISORDERS | The University Court Of The University of Edinburgh (GB) | 2024-12-11 | — | — | EP | disclosed |
| US-20240384267-A1 | COMPOSITIONS AND METHODS FOR MULTIPLEX DECODING OF QUADRUPLET CODONS | THE BROAD INSTITUTE, INC. | 2024-11-21 | — | — | US | disclosed |
| CN-118696126-A | Recombinant optimized MECP2 cassettes and methods for treating Rate syndrome and related disorders | 爱丁堡大学董事会 | 2024-09-24 | — | — | CN | disclosed |
| WO-2024052694-A2 | THERAPEUTIC MOLECULES | UEA ENTERPRISES LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| EP-2018437-A2 | NON-NATURAL AMINO ACID SUBSTITUTED POLYPEPTIDES | Allozyne, Inc. (US) | 2009-01-28 | — | — | EP | disclosed |
| EP-1999259-A2 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | California Institute of Technology (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20080214439-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080200641-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080125347-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080096819-A1 | Amino acid substituted molecules | ALLOZYNE, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080044854-A1 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2007149852-A2 | MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007130453-A2 | NON-NATURAL AMINO ACID SUBSTITUTED POLYPEPTIDES | ALLOZYNE, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007103307-A2 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096819-A1 | Amino acid substituted molecules | BCAT2, DNPEP, PTMS | ALDH1A1 2926/4885LMNA 3746/4885THRB 4351/4885 |
| US-20080214439-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | ALDH1A1 2926/4885LMNA 3746/4885THRB 4351/4885 |
| US-20080200641-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | ALDH1A1 2926/4885LMNA 3746/4885THRB 4351/4885 |
| US-20080044854-A1 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | AARS1, TRMT1, NSUN3 | ALDH1A1 4016/4885LMNA 3850/4885THRB 2057/4885 |
| US-20080125347-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | ALDH1A1 2926/4885LMNA 3746/4885THRB 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.